Oncology

Latest News

Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap
Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap

August 21st 2025

RIsing costs for therapies and inequities in reimbursement for genomic testing have created financial barriers for patients, according to appearing experts in Detroit, Michigan, on July 10, 2025.

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
Predictive Model Forecasts Advanced NSCLC Outcomes

August 14th 2025

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi
Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com
Legal Navigation Services Key to Addressing Disparities in Cancer Care

July 31st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 23rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 23rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
April 23rd 2025

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

AJMC Contributor
Even with prevention measures and timely, aggressive intervention, tumor lysis syndrome (TLS) remains life-threatening, as a case study in small cell lung cancer (SCLC) illustrates.
Diabetes monitoring | Image credit: abidika - stock.adobe.com
April 23rd 2025

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

Pearl Steinzor
A new study has found increased risks for liver, pancreatic, and bowel cancers following a new diagnosis of type 2 diabetes—but not all obesity-related cancers show a link.
Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com
April 23rd 2025

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

Pearl Steinzor
Emerging research highlights how vitamin D boosts immunity and reduces colorectal cancer (CRC) risk by regulating inflammation and cell growth.
Andrew Chapman, DO
April 23rd 2025

“Flipping the Script” to Reshape Access, Redefine Value in Oncology: Andrew Chapman, DO

Kyle Munz Andrew Chapman, DO
"Value" in oncology should measure far more than clinical outcomes, stated Andrew Chapman, DO, as he argued how rethinking "value" could not only enhance patient care but also drive down costs.
The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com
April 22nd 2025

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

Rose McNulty
Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Patient navigation | Image credit: AON
April 22nd 2025

With Thyme Care Partnership, AON Achieves $6M in Savings in EOM’s First Performance Period

Mary Caffrey
Within 5 years, the risk of SCC in particular was heightened among patients with MMP. | Image credit: wavebreak3 - stock.adobe.com
April 21st 2025

Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers

AJMC Contributor
The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.
AI technology | Image: Adobe Stock
April 17th 2025

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

Mary Caffrey
These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
April 14th 2025

Building Communities Around Patients: Cathy Eng, MD

Maggie L. Shaw Cathy Eng, MD, FACP, FASCO
Cathy Eng, MD, FACP, FASCO, participated on the panel discussion, “Health Equity in Cancer Care Delivery,” during the January Institute for Value-Based Medicine® event, “Elevating Value in Cancer Care: Nashville.”
IVBM Atlanta | Image credit: AJMC
April 14th 2025

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

Kyle Munz
Coverage from the Atlanta Regional meeting of the Institute for Value-Based Medicine.
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
April 9th 2025

How AI, Data Analytics, and Outcomes-Based Contracts Are Shaping Health Care: Laura Bobolts, PharmD, BCOP

Pearl Steinzor Laura R. Bobolts, PharmD, BCOP
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, shares how health care leaders are advancing value-based care through improved data strategies, real-world evidence, and AI-driven efficiencies, without losing the human touch.
Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg
April 9th 2025

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

Giuliana Grossi
New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
AJMC
April 4th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

Galen Shearn-Nance, BS Rishi R. Sachdev, BS Long Vu, MS Weichuan Dong, PhD Alberto J. Montero, MD, MBA Siran M. Koroukian, PhD Johnie Rose, MD, PhD
This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com
April 2nd 2025

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

Hayden E. Klein
After fine-tuning, the VGG16 convolutional neural network outperformed other deep learning models in 2 of 3 key classification tasks.
Long-Term Effects of COVID-19 Disruptions on Cancer Care Still Unfolding: Dan Nardi, MS
April 1st 2025

Long-Term Effects of COVID-19 Disruptions on Cancer Care Still Unfolding: Dan Nardi, MS

Brooke McCormick Dan Nardi, MS
The long-term impact of disruptions in oncology care during the COVID-19 pandemic will become more apparent in the coming years, according to Dan Nardi, MS, of Reimagine Care.
Round FDA approval stamp in blue ink | Image Credit: © Surendra - stock.adobe.com
March 31st 2025

FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

Maggie L. Shaw
The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.
FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com
March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Doctor showing patient x-ray of lung cancer. | Image credit: Nattakorn – stock.adobe.com
March 25th 2025

3 DDR Phenotypes May Predict Chemotherapy Response in SCLC

Hayden E. Klein
One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.
Cathy Eng, MD, FACP, FASCO
March 24th 2025

Elevating Cancer Care Through Personalized Treatment

Maggie L. Shaw Cathy Eng, MD, FACP, FASCO
In this discussion with Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, she illustrates how Vanderbilt works to specify each individual patient’s cancer care regimen and treatment path.
Estrogen | Image credit: Debalina - stock.adobe.com
March 20th 2025

Estrogen Therapy May Increase Risk of 3 Skin Cancers

Hayden E. Klein
Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, but did not recommend discontinuation of any of the drugs studied.
Karen Winkfield, MD, PhD
March 19th 2025

Expanding Access to Clinical Trials Through Community Partnerships

Maggie L. Shaw Karen Winkfield, MD, PhD
Karen Winkfield, MD, PhD, addresses the importance of meeting patients where they are to expand clinical trial participation and remove barriers to trial access.
Texas Oncology logo | Image: Texas Oncology
March 18th 2025

Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot

Mary Caffrey Rose McNulty
Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year
March 17th 2025

Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year

Mary Caffrey
As St. Patrick's Day brings global celebrations involving alcohol, Ireland looks forward to rethinking excess consumption with a new tool set to arrive next year: the world's most comprehensive alcohol warning label.
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
March 15th 2025

How Do Infusion Pharmacies Support Financial Sustainability in Oncology?

Hayden E. Klein Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Jorge García, PharmD, MS, MBA, MHA, highlights the need for infusion pharmacy optimization to sustain oncology care amid rising costs and evolving value-based reimbursement models.
Doctor screening patient for skin cancer | Image credit: Seventyfour – stock.adobe.com
March 14th 2025

Patients Prefer AI in Skin Cancer Screening as an Assistive Tool, Not a Replacement

Hayden E. Klein
Patients expressed concern that overreliance on artificial intelligence (AI) could lead to clinicians losing their skills, both medical and interpersonal.
The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle
March 9th 2025

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

Mary Caffrey
Experts shared details on health care contracting, setting up a centralized prior authorization pilot, and use of advocacy to win pharmacy benefit manager reforms at the state level.
Doctor conducting a skin cancer check | Image credit: InsideCreativeHouse - stock.adobe.com
March 6th 2025

Image-Guided Superficial Radiation Therapy Safe, Effective Treatment for Nonmelanoma Skin Cancer: Expert Panel

Emma Andrus
A dermatology expert panel confirms image-guided superficial radiation therapy as a safe, effective first-line treatment for select nonmelanoma skin cancer cases.
lung cancer | Image credit: Crystal light - stock.adobe.com
March 5th 2025

Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors

Jordyn Sava
Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing small cell lung cancer and neuroendocrine carcinoma.
DNA strand | Image: FreePik
March 4th 2025

Technology, Partnerships, Data, and Culture Are Keys to Bringing Precision Medicine to Community Oncology

Mary Caffrey
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Published: March 4th 2025 | Updated: March 4th 2025

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Rose McNulty
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.
<12345678
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo